What Are Therapeutic Peptides? Pharmacology, History & Clinical Applications

A therapeutic peptide is a rigorously characterized pharmaceutical entity consisting of an organized sequence of amino acids (typically between 2 and 50 residues) manufactured under Good Manufacturing Practice (GMP) standards to treat specific clinical indications [1].

Unlike dietary protein powders or unverified research chemicals sold without regulatory scrutiny, therapeutic peptides undergo extensive preclinical toxicology, Pharmacokinetics/Pharmacodynamics (PK/PD) characterization, Phase 1–3 human clinical trials, and formal approval by regulatory agencies such as the U.S. FDA, European Medicines Agency (EMA), or PMDA [1].

In modern pharmacology, drug discovery is traditionally divided into two distinct modalities: small synthetic chemical molecules (< 500 Da) and large biologics (typically > 5,000 Da, and roughly 150,000 Da for monoclonal antibodies), which are not orally bioavailable and generally require injection. Peptides sit between these extremes and can combine some advantages of each [2]:

• Compared to Small Molecules: Peptides make many more contacts with their targets, allowing them to target shallow protein-protein interaction (PPI) interfaces that small molecules cannot engage. This tends to give them high target specificity and potency.
• Compared to Monoclonal Antibodies: Many peptides can be produced by chemical synthesis (SPPS) rather than in cell-based bioreactors, and their smaller size can favour lower cost and better membrane permeability, although poor bioavailability and metabolic instability remain key challenges [2].

The history of peptide therapeutics spans over a century of biochemical breakthroughs [3]:

• 1922: Extraction of animal pancreatic insulin transforms fatal type 1 diabetes into a manageable condition.
• 1954: Vincent du Vigneaud completes the total chemical synthesis of oxytocin, establishing the field of synthetic peptide pharmaceuticals.
• 1982: Recombinant human insulin (Humulin) becomes the world's first genetically engineered pharmaceutical drug.
• 1988: Octreotide is approved as a stabilized somatostatin analogue, establishing the value of cyclic peptide design.
• 2005–Present: Incretin mimetics (exenatide, liraglutide, semaglutide, tirzepatide) establish new standards of care across diabetes, obesity, and cardiovascular risk reduction [3].

Over 80 therapeutic peptides are approved globally across diverse clinical disciplines [1]:

• Metabolic & Endocrine: Insulins, GLP-1 receptor agonists (semaglutide), dual GIP/GLP-1 agonists (tirzepatide), glucagon, pramlintide, and tesamorelin.
• Oncology & Endocrinology: GnRH agonists/antagonists (leuprolide, degarelix), somatostatin analogues (octreotide, lanreotide) for neuroendocrine tumors and acromegaly.
• Bone Health: Teriparatide (PTH 1-34) and abaloparatide (PTHrP analogue) for severe osteoporosis.
• Gastrointestinal & Critical Care: Linaclotide (guanylate cyclase-C agonist for IBS-C), vasopressin for septic shock, and oxytocin for labor augmentation.
• Infectious Disease: Peptide antibiotics including polymyxin B, colistin, daptomycin, and enfuvirtide (HIV fusion inhibitor) [1].

The frontier of peptide drug design is moving toward targeted delivery vehicles [4]. In Peptide-Drug Conjugates (PDCs), high-affinity peptides are chemically tethered to potent cytotoxic payloads, delivering chemotherapeutics selectively to malignant cells expressing specific receptors.

Similarly, in peptide receptor radionuclide therapy (PRRT), exemplified by lutetium Lu-177 dotatate (Lutathera), radiolabeled somatostatin analogues deliver targeted ionizing radiation directly to somatostatin receptor-positive neuroendocrine tumors, sparing healthy surrounding tissue [4].